Antiepileptic drugs /

Antiepileptic drugs /

Saved in:
Bibliographic Details
Edition:5th ed.
Imprint:Philadelphia : Lippincott Williams & Wilkins, c2002.
Description:xv, 968 p. : ill. ; 29 cm.
Language:English
Subject:
Epilepsy -- Chemotherapy.
Anticonvulsants.
Anticonvulsants -- therapeutic use.
Anticonvulsants -- pharmacology.
Epilepsy -- drug therapy.
Anticonvulsants.
Epilepsy -- Chemotherapy.
Format: Print Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/4746692
Hidden Bibliographic Details
Other authors / contributors:Levy, René H.
ISBN:0781723213
Notes:Includes bibliographical references and index.

MARC

LEADER 00000pam a22000004a 4500
001 4746692
003 ICU
005 20031021183400.0
008 020722s2002 paua b 001 0 eng
010 |a  2002030011 
020 |a 0781723213 
035 |a 2002030011 
035 |a (DNLM)101150747 
040 |a DNLM/DLC  |c DLC  |d NhCcYBP  |d OCoLC  |d OrLoB-B 
042 |a pcc 
050 0 0 |a RC374.C48  |b A58 2002 
060 1 0 |a QV 85  |b A628 2002 
082 0 0 |a 616.8/53061  |2 21 
245 0 0 |a Antiepileptic drugs /  |c editors, René H. Levy ... [et al.]. 
250 |a 5th ed. 
260 |a Philadelphia :  |b Lippincott Williams & Wilkins,  |c c2002. 
300 |a xv, 968 p. :  |b ill. ;  |c 29 cm. 
336 |a text  |b txt  |2 rdacontent  |0 http://id.loc.gov/vocabulary/contentTypes/txt 
337 |a unmediated  |b n  |2 rdamedia  |0 http://id.loc.gov/vocabulary/mediaTypes/n 
338 |a volume  |b nc  |2 rdacarrier  |0 http://id.loc.gov/vocabulary/carriers/nc 
504 |a Includes bibliographical references and index. 
505 0 0 |g Sect. I.  |t General Principles --  |g 1.  |t Principles of Antiepileptic Drug Action /  |r Michael A. Rogawski --  |g 2.  |t Neurophysiological Effects of Antiepileptic Drugs /  |r Carl W. Bazil and Timothy A. Pedley --  |g 3.  |t Discovery and Preclinical Development of Antiepileptic Drugs /  |r H. Steve White, Jose H. Woodhead and Karen S. Wilcox /  |r [et al.] --  |g 4.  |t New Antiepileptic Drug Development: Medical Perspective /  |r Jacqueline A. French and Marc A. Dichter --  |g 5.  |t Clinical Development of Antiepileptic Drugs: Industry Perspective /  |r Roger J. Porter --  |g 6.  |t The Development of Antiepilepsy Drugs: Regulatory Perspective /  |r Russell Katz --  |g 7.  |t Antiepileptic Drug Monotherapy in Adults: Selection and Use in New-Onset Epilepsy /  |r Richard H. Mattson --  |g 8.  |t Combination Therapy and Drug Interactions /  |r Emilio Perucca and Rene H. Levy --  |g 9.  |t Laboratory Monitoring of Antiepileptic Drugs /  |r Svein I. Johannessen and Torbjorn Tomson --  |g 10.  |t Safety Monitoring of Antiepileptic Drugs /  |r L. James Willmore --  |g 11.  |t Use of Antiepileptic Drugs in Children /  |r Olivier Dulac --  |g 12.  |t Antiepileptic Drug Use in Women /  |r Martha J. Morrell --  |g 13.  |t Epilepsy in the Elderly /  |r Ilo E. Leppik and James C. Cloyd --  |g 14.  |t Treatment of Status Epilepticus /  |r Brian K. Alldredge --  |g 15.  |t Prevention of Epileptogenesis /  |r Asla Pitkanen --  |g Sect. II.  |t Benzodiazepines --  |g 16.  |t Mechanisms of Action /  |r Robert L. Macdonald --  |g 17.  |t Chemistry, Biotransformation, and Pharmacokinetics /  |r Gail D. Anderson and John W. Miller --  |g 18.  |t Clinical Efficacy and Use in Epilepsy /  |r Dieter Schmidt --  |g 19.  |t Adverse Effects /  |r Roberto Michelucci and Carlo Alberto Tassinari --  |g Sect. III.  |t Carbamazepine --  |g 20.  |t Mechanisms of Action /  |r Robert L. Macdonald --  |g 21.  |t Chemistry, Biotransformation, and Pharmacokinetics /  |r Edoardo Spina --  |g 22.  |t Interactions with Other Drugs /  |r Colleen J. Wurden and Rene H. Levy --  |g 23.  |t Clinical Efficacy and Use in Epilepsy /  |r Pierre Loiseau --  |g 24.  |t Clinical Efficacy and Use in Other Neurological Disorders /  |r Ettore Beghi --  |g 25.  |t Clinical Efficacy and Use in Psychiatric Disorders /  |r Michael R. Trimble --  |g 26.  |t Adverse Effects /  |r Gregory L. Holmes --  |g Sect. IV.  |t Felbamate --  |g 27.  |t Felbamate /  |r John M. Pellock, James L. Perhach and R. Duane Sofia --  |g Sect. V.  |t Gabapentin --  |g 28.  |t Mechanisms of Action /  |r Charles P. Taylor --  |g 29.  |t Chemistry, Biotransformation, Pharmacokinetics, and Interactions /  |r Frank J. E. Vajda --  |g 30.  |t Clinical Use /  |r Anthony G. Marson and David W. Chadwick --  |g 31.  |t Clinical Efficacy and Use in Other Neurological Disorders /  |r Bernd Schmidt --  |g 32.  |t Clinical Efficacy and Use in Psychiatric Disorders /  |r John H. Greist --  |g 33.  |t Adverse Effects /  |r R. Eugene Ramsay and Flavia M. Pryor --  |g Sect. VI.  |t Lamotrigine --  |g 34.  |t Mechanisms of Action /  |r Michael J. Leach, Andrew D. Randall and Alessandro Stefani /  |r [et al.] --  |g 35.  |t Chemistry, Biotransformation, and Pharmacokinetics /  |r Maurice Dickins and Chao Chen --  |g 36.  |t Interactions with Other Drugs /  |r William R. Garnett --  |g 37.  |t Clinical Efficacy and Use in Epilepsy /  |r Linda J. Stephen and Martin J. Brodie --  |g 38.  |t Efficacy and Use in Nonepileptic Disorders /  |r Melvin D. Shelton and Joseph R. Calabrese --  |g 39.  |t Adverse Effects /  |r Francesco Pisani and Alan Richens --  |g Sect. VII.  |t Levetiracetam --  |g 40.  |t Mechanisms of Action /  |r Doru Georg Margineanu and Henrik Klitgaard --  |g 41.  |t Chemistry, Biotransformation, Pharmacokinetics, and Drug Interactions /  |r Philip N. Patsalos --  |g 42.  |t Clinical Use /  |r Ilo E. Leppik --  |g 43.  |t Adverse Experiences /  |r Victor Biton --  |g Sect. VIII.  |t Oxcarbazepine --  |g 44.  |t Mechanisms of Action /  |r Michael J. McLean --  |g 45.  |t Chemistry, Biotransformation, and Pharmacokinetics /  |r Meir Bialer --  |g 46.  |t Interactions with Other Drugs /  |r Fiorenzo Albani, Roberto Riva and Agostino Baruzzi --  |g 47.  |t Clinical Efficacy and Use in Epilepsy /  |r Steven C. Schachter --  |g 48.  |t Clinical Efficacy and Use in Psychiatric Disorders /  |r Michael R. Trimble --  |g 49.  |t Adverse Effects /  |r Gunter Kramer --  |g Sect. IX.  |t Phenobarbital and Other Barbiturates --  |g 50.  |t Mechanisms of Action /  |r Richard W. Olsen --  |g 51.  |t Chemistry, Biotransformation, and Pharmacokinetics /  |r Gail D. Anderson --  |g 52.  |t Interactions with Other Drugs /  |r J. Steven Leeder --  |g 53.  |t Clinical Efficacy and Use in Epilepsy /  |r Michel Baulac --  |g 54.  |t Clinical Efficacy and Use in Nonepileptic Disorders /  |r Ettore Beghi --  |g 55.  |t Adverse Effects /  |r Michel Baulac, Joyce A. Cramer and Richard H. Mattson --  |g 56.  |t Methylphenobarbital /  |r Mervyn J. Eadie and Wayne D. Hooper --  |g Sect. X.  |t Phenytoin and Other Hydantoins --  |g 57.  |t Mechanisms of Action /  |r Robert J. DeLorenzo and David A. Sun --  |g 58.  |t Chemistry and Biotransformation /  |r Thomas R. Browne and Barbara LeDuc --  |g 59.  |t Interactions with Other Drugs /  |r Isabelle Ragueneau-Majlessi, Manoj Bajpai and Rene H. Levy --  |g 60.  |t Clinical Efficacy and Use in Epilepsy /  |r B. Joe Wilder and Joseph Bruni --  |g 61.  |t Clinical Efficacy and Use in Other Neurological Disorders /  |r Ettore Beghi --  |g 62.  |t Clinical Efficacy and Use in Psychiatric Disorders /  |r Francesco Monaco and Marco Mula --  |g 63.  |t Adverse Effects /  |r Joseph Bruni --  |g 64.  |t Fosphenytoin /  |r Flavia M. Pryor and R. Eugene Ramsay --  |g Sect. XI.  |t Primidone --  |g 65.  |t Primidone /  |r Richard W. Fincham and Dorothy D. Schottelius --  |g Sect. XII.  |t Succinimides --  |g 66.  |t Mechanisms of Action /  |r Katherine D. Holland and James A. Ferrendelli --  |g 67.  |t Ethosuximide: Chemistry, Biotransformation, Pharmacokinetics, and Drug Interactions /  |r Francesco Pisani, Emilio Perucca and Meir Bialer --  |g 68.  |t Clinical Efficacy and Use in Epilepsy /  |r Allan L. Sherwin --  |g 69.  |t Adverse Effects /  |r Tracy A. Glauser --  |g 70.  |t Methsuximide /  |r Thomas R. Browne --  |g Sect. XIII.  |t Tiagabine --  |g 71.  |t Mechanisms of Action /  |r William J. Giardina --  |g 72.  |t Chemistry, Biotransformation, and Pharmacokinetics /  |r Kenneth W. Sommerville and Stephen D. Collins --  |g 73.  |t Drug Interactions /  |r Kenneth W. Sommerville --  |g 74.  |t Clinical Efficacy and Use in Epilepsy /  |r Reetta Kalviainen --  |g 75.  |t Clinical Efficacy and Use in Nonepileptic Disorders /  |r Kenneth W. Sommerville --  |g 76.  |t Adverse Effects /  |r Steven C. Schachter --  |g Sect. XIV.  |t Topiramate --  |g 77.  |t Mechanisms of Action /  |r H. Steve White --  |g 78.  |t Chemistry, Biotransformation, and Pharmacokinetics /  |r Dennis R. Doose and Anthony J. Streeter --  |g 79.  |t Drug Interactions /  |r Barry E. Gidal --  |g 80.  |t Clinical Efficacy and Use in Epilepsy /  |r Michael D. Privitera and Roy E. Twyman --  |g 81.  |t Clinical Efficacy and Use in Nonepileptic Disorders /  |r Marc Kamin --  |g 82.  |t Adverse Effects /  |r Rajesh C. Sachdeo and Roopal M. Karia --  |g Sect. XV.  |t Valproic Acid --  |g 83.  |t Mechanisms of Action /  |r Wolfgang Loscher --  |g 84.  |t Chemistry, Biotransformation, and Pharmacokinetics /  |r Rene H. Levy, Danny D. Shen and Frank S. Abbott /  |r [et al.] --  |g 85.  |t Drug Interactions /  |r Richard D. Scheyer --  |g 86.  |t Clinical Efficacy and Use in Epilepsy /  |r Blaise F. D. Bourgeois --  |g 87.  |t Clinical Efficacy and Use in Other Neurological Disorders /  |r Stephen D. Silberstein --  |g 88.  |t Clinical Efficacy and Use in Psychiatric Disorders /  |r Alan C. Swann --  |g 89.  |t Adverse Effects /  |r Pierre Genton and Philippe Gelisse --  |g Sect. XVI.  |t Vigabatrin --  |g 90.  |t Vigabatrin /  |r Elinor Ben-Menachem --  |g Sect. XVII.  |t Zonisamide --  |g 91.  |t Mechanisms of Action /  |r Robert L. Macdonald --  |g 92.  |t Chemistry, Biotransformation, and Pharmacokinetics /  |r Jaymin Shah, Kent Shellenberger and Daniel M. Canafax --  |g 93.  |t Drug Interactions /  |r Gary G. Mather and Jaymin Shah --  |g 94.  |t Clinical Efficacy and Use in Epilepsy /  |r Masakazu Seino and Buichi Fujitani --  |g 95.  |t Adverse Effects /  |r Byung In Lee --  |g Sect. XVIII.  |t Drugs in Development --  |g 96.  |t Pregabalin /  |r Elinor Ben-Menachem and Alan R. Kugler --  |g 97.  |t Rufinamide /  |r Mary Ann Karolchyk and Dieter Schmidt --  |g 98.  |t Drugs in Early Clinical Development /  |r Emilio Perucca and Harvey J. Kupferberg. 
650 0 |a Epilepsy  |x Chemotherapy.  |0 http://id.loc.gov/authorities/subjects/sh2008119833 
650 0 |a Anticonvulsants.  |0 http://id.loc.gov/authorities/subjects/sh85005657 
650 1 2 |a Anticonvulsants  |x therapeutic use. 
650 2 2 |a Anticonvulsants  |x pharmacology. 
650 2 2 |a Epilepsy  |x drug therapy. 
650 7 |a Anticonvulsants.  |2 fast  |0 http://id.worldcat.org/fast/fst00810472 
650 7 |a Epilepsy  |x Chemotherapy.  |2 fast  |0 http://id.worldcat.org/fast/fst00914186 
700 1 |a Levy, René H.  |0 http://id.loc.gov/authorities/names/n82251883  |1 http://viaf.org/viaf/51805614 
901 |a ToCBNA 
903 |a HeVa 
035 |a (OCoLC)50285309 
929 |a cat 
999 f f |i c0fb4d81-cdb7-50e1-8804-988ae6c9705f  |s 03c1eb11-ba84-5ce8-8dbc-847a7ebffd90 
928 |t Library of Congress classification  |a RC374.C48 A58 2002  |l JCL  |c JCL-Sci  |i 6438366 
927 |t Library of Congress classification  |a RC374.C48 A58 2002  |l JCL  |c JCL-Sci  |e MARO  |e CRERAR  |b 61105366  |i 7350441 
Given by Samuel R. & Marie-Louise Rosenthal in memory of Martin R. Rosenthal bookplate
The John Crerar Library bookplate

Similar Items